Glutamate (GLU)-induced excitotoxicity is considered to be a frequent cause of cell degeneration in basal ganglia disorders; it is normally prevented by uptake of GLU by astrocytes. We recently found that transient perfusion of GLU in the striatum induces persistent accumulation of GLU in striatal astrocytes that could be from the initial administration or caused by the slow release from neurons or astrocytes in response to it. Endogenous production of GLU, that is, ''self-induced GLU accumulation'' (SIGA), may occur under physiological and pathological conditions. Here we studied the possible induction of SIGA after injury induced by perfusion of GLU receptor agonists into the striatum of rats. The agonists induced local degeneration in neurons and myelinated axons and microgliosis and astrocytosis; there was also gliosis and remote degeneration of neurons in the ventral-posterior complex of the thalamus that project to the cerebral cortex across the striatum. Reactive astrocytes showed persistent GLU accumulation in the striatum (local SIGA) and thalamus (remote SIGA) that persisted for at least 6 weeks after the injury. Thus, SIGA can be induced by neuronal degeneration retrogradely triggered from a remote brain region after excessive release of endogenous GLU from astrocytes. This may be an additional factor to be considered in basal ganglia disorders with glutamatergic excitotoxicity.
INTRODUCTION
The excessive release of neuronal glutamate (GLU) may induce neurodegeneration (excitotoxicity) in basal ganglia disorders such as Huntington disease (1Y3) and Parkinson disease (4Y10). Excitotoxic activity of neuronal GLU is normally prevented by the astrocytic uptake of GLU (11Y18), but the roles of astrocytes may be more complex than simply preventing excitotoxicity. An excessive release of neuronal GLU modifies astrocytes (19, 20) , such that they begin to release toxic agents (e.g. reactive oxygen species and nitric oxide) that can stimulate microglia (15, 18, 21Y25) and promote the degeneration of the surrounding cells (16, 23) . Astrocytes have a high cytosolic concentration of GLU (1Y3 mmol/L), the release of which to the extracellular medium (G50 Kmol/L) may be a mechanism that accelerates excitotoxicity (15) . Therefore, the relationship between GLU and astrocytes may change, protecting neurons from GLU excess when under normal conditions (26Y28) and releasing GLU and inducing neuronal damage when they become reactive (16) . The relative importance of the toxic and protective role of astrocytes and the relevance of astrogliosis on the evolution of brain lesions are still matters of debate (15, 16, 19) .
We recently found that striatal perfusion of GLU induces marked accumulation of the amino acid in astrocytes, that is, self-induced GLU accumulation (SIGA) (29) . Although GLU was perfused for a short time (1 hour), we observed that SIGA persisted during a long time interval (6 weeks after GLU administration). In view of the number of stimuli (e.g. swelling, reactive oxygen species) and mechanisms (reverse operation of GLU transporters, opening of anion channels or hemichannels) that are capable of activating the glial release of GLU, this suggests that SIGA is a potential risk factor to the surrounding cells. The long persistence of SIGA was associated with downregulation of glutamine synthetase activity, suggesting that GLU molecules accumulated in these cells were mainly those perfused at the beginning of the experiment (29) . Glutamate perfusion also induced progressive degeneration of the surrounding glutamatergic synapses. The GLU concentration of glutamatergic synapses is 3 to 6 mmol/L, whereas in astrocytes, it is 1 to 2 mmol/L, suggesting that SIGA may be involved not only in conditions with massive and transient releases of GLU, such as epileptic seizures (15, 21) , but also in conditions in which neuronal release of GLU is less marked but more persistent, such as Parkinson disease and Huntington disease. Thus, an understanding of mechanisms involved in SIGA and in the glial release of GLU (13, 14, 30Y32) may be important in developing strategies to prevent excitotoxicity in these chronic conditions.
The aim of this study was to determine whether the striatal SIGA induced by the local administration of GLU can be activated by facilitating release of endogenous GLU. In addition, the possibility that the striatal activation of SIGA may affect axons that cross the striatum, generating remote SIGA in the brain region where the cell somata of these axons are located (remote SIGA), was also studied.
Remote SIGA was evaluated in the ventral-posterior complex of the thalamus in which the neurons send axons across the striatum to the cerebral cortex. The release of endogenous GLU was produced by degenerating cells with glutamatergic agonists perfused by reverse microdialysis, a procedure that induces minimal nonspecific lesions (29, 33) .
MATERIALS AND METHODS
Experiments were carried out on male Sprague-Dawley rats weighing 300 to 350 g. Animals were housed at 22-C, 2 per cage, under normal laboratory conditions on a standard light-dark schedule (12:12, with 8:00 AM-8:00 PM light on) and with free access to food and water. Experiments were conducted in accordance with the European Communities Council Directive of November 24, 1986 (86/609/EEC) regarding the care and use of animals for experimental procedures, and adequate measures were taken to minimize pain and discomfort.
Microdialysis
Microdialysis was performed according to previously reported procedures (14, 30) . Animals were initially anesthetized with Equitensin (pentobarbital 29 mg/kg, chloral hydrate 127.5 mg/kg, MgSO 4 71.4 mg/kg, dihydroxypropane 40%, and ethanol 10%). To maintain long-lasting stable anesthesia, they were then continuously perfused intraperitoneally with Equitensin (0.5 mL/hour beginning 60 minutes after the initial intraperitoneal administration of the anesthetic). Body temperature was monitored and maintained between 36.5-C and 37.0-C for the entire period. A concentric microdialysis probe (220 Km diameter, 3 mm long, and in vitro recovery of È15% for amino acids) was introduced in the striatum (1.0 mm anterior to bregma, 2.5 mm lateral to the midline, and 7.5 mm under the cortical surface) at a rate of 100 Km/minute to prevent nonspecific lesions during the tissue penetration. Rats were perfused with a Ringer solution (NaCl, 148 mmol/L; KCl, 2.7 mmol/L; CaCl 2 , 1.2 mmol/L; and MgCl 2 , 0.8 mmol/L) at the beginning of each experiment (first 90 minutes), and then a 0.5-mmol/L solution of RS->-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid hydrobromide ([AMPA] Sigma-Aldrich, Madrid, Spain); kainic acid, Sigma-Aldrich), or 0.5 mmol/L N-methyl-o-aspartic acid ([NMDA] Sigma-Aldrich) was perfused for 60 minutes. All solutions were perfused at a rate of 2.0 KL/minute. The effects of sham perfusion and of AMPA, kainate, and NMDA perfusion were studied in 6, 8, 7, and 7 rats, respectively. The recovery rate of the microdialysis probe was tested in vitro at the beginning of each experiment using a high-performance liquid chromatography system with fluorometric detection and following previously reported procedures (34, 35) .
Histology
At 6 weeks after the end of each experiment, the rats were transcardially perfused with 200 mL of 0.9% saline solution followed by 400 mL of 4% paraformaldehyde in 0.1 mol/L PBS (pH 7.4). Brains were removed and stored in the same fixative at 4-C for 4 hours, immersed in a cryoprotective solution of 30% sucrose in the same buffer for 48 hours, and then cut at 30 Km with a sliding microtome (HM 450, MICROM International, Walldorf, Germany). To observe the effect of injected drugs at different distances from the microdialysis probe, brains were cut following axial planes parallel to the surface of the cortex and perpendicular to the probe trajectory. Sections were collected in 7 parallel series and processed for immunohistochemistry. Floating sections were immersed for 30 minutes in 3% H 2 O 2 to inactivate endogenous peroxidase and incubated for 60 minutes at room temperature in 4% normal goat serum ([NGS] Sigma-Aldrich) in PBS, containing 0.05% Triton X-100(TX-100; Sigma-Aldrich), and overnight in PBS containing 2% NGS and one of the following primary antibodies: mouse antiYglial fibrillary acidic protein (anti-GFAP) monoclonal antibody (1:800; Chemicon, Millipore, Molsheim, France), rabbit anti-GFAP polyclonal antibody (1:1000; Sigma), rabbit anti-GLU polyclonal antibody (1:1000; Sigma), mouse anti-macrosialin (anti-CD68) monoclonal antibody (1:1000; ABD Serotec, Bionova, Madrid, Spain), and mouse anti-NeuN monoclonal antibody (1:600; Chemicon, Millipore).
For double and triple immunofluorescent labeling, sections were first incubated for 1 hour in 4% NGS and 0.05% TX-100 in PBS and overnight in the same solution containing the rabbit anti-GLU and mouse anti-GFAP, or chicken anti-GFAP and mouse anti-CD68 and rabbit anti-GLU. After several rinses, sections were mounted on gelatinized slides, air-dried, coverslipped with Vectashield (Vector Laboratories, Burlingame, CA), and examined under confocal microscopy (Olympus FluoView FV1000) using appropriate filters. Control experiments were performed for each immunocytochemistry and immunofluorescence study by removing the primary antibody, resulting in negative staining.
Astrocytic reaction to NMDA, kainate, or AMPA administration was evaluated by comparing the GFAP immunoreactivity (immunofluorescence intensity) in the striatum around the microdialysis probe and in the ventral-posterior complex of the thalamus of the perfused and the contralateral brain sides. Because numerous variables produced intertrial fluctuations of immunostaining data were normalized to those obtained in the same striatal or thalamic regions of the contralateral side, that is, data were calculated as percentages of the mean value of the astrocytic processes of the contralateral striatum or thalamus. At least 2,000 astrocytic processes were evaluated in each experimental condition in 10 Â 10 Â 2YKm images obtained with a spatial resolution of 1,025 Â 1,025 pixels. In each brain slice, the same numbers of astrocytic processes were computed in the striatum and thalamus of both sides. The value used to represent the immunoreactivity of each astrocytic process was the average of 3,000 of the most immunoreactive voxels. Measurements were performed with the FV10-ASW (version 01.07.01.00) software (Olympus Corporation). A similar procedure was used to compute GLU immunoreactivity in the astrocytic processes. Glutamate immunoreactivity was quantified in the astrocytic processes identified by the presence of GFAP immunoreactivity, and the average GLU immunoreactivity of the 3,000 pixels that showed the highest GFAP immunoreactivity in each astrocytic process was computed. Different calculations were performed for protoplasmic and fibrous astrocytes, and at least 2,000 astrocytic processes were computed in each experimental condition, astrocytic type, and brain region analyzed. To prevent differences caused by variations in protocol conditions during tissue processing and densitometric analysis, all sections were processed simultaneously using the same protocols and chemical reagents, and all microscopic and computer parameters were kept constant throughout the densitometric study. The position and boundaries of fiber tracts within the striatum were located using phase-contrast microscopy (shown in black and white images in the figures). Astrocytes were considered fibrous if they were located within fiber tracts and had long slender processes, most of which were parallel to the tracts. Protoplasmic astrocytes were located in the gray matter and exhibited numerous short and highly ramified processes with many membranous extensions (19) . Fibrous astrocytes were not studied in the thalamus because they could not be clearly distinguished in this region from protoplasmic astrocytes. No radial-like astrocytes were found in the thalamus.
Striatal degeneration was computed by counting NeuNpositive cells 0 to 200 Km, 200 to 400 Km, and 400 to 600 Km around the microdialysis probe, and numbers were normalized to numbers of neurons counted in the same areas of the contralateral striatum. The retrograde degeneration of thalamic NeuN-positive cells was assessed in the ventral-posterior complex of the thalamus (ventral posterolateral thalamic nucleus and ventral posteromedial thalamic nucleus); these data were also normalized to neuron numbers in the same areas of the contralateral thalamus. Thalamic microgliosis was studied by counting the number of reactive microglia (CD68-positive cells) in the ventral-posterior complex of the thalamus. Numbers of microglial cells and neurons were computed with the ImagePro Plus software (Media Cybernetics, Rockville, MD).
Degeneration of striatal bundles of myelinated axons around the microdialysis probe was observed with the BlackGold II method (36, 37) .
Statistics
Mathematical analyses were performed using the oneway analysis of variance followed by the Scheffé test for post hoc comparisons. Analysis was performed using the Statistic program (StatSoft, Tulsa, OK). A level of p G 0.05 was considered significant.
RESULTS
The microdialysis probe insertion and GLU vehicle perfusion induced minimal nonspecific effects in the striatum (Fig. 1A) that were confined within the 200 Km around the microdialysis probe (sham group in Fig. 1EYG ). The vehicle perfusion did not induce microgliosis or neuronal loss in the ventral-posterior complex of the thalamus.
The administration of AMPA (Fig. 1B) , kainate (Fig. 1C) , and NMDA (Fig. 1D) induced degeneration of myelinated axons (compare the example of the striatal area perfused with AMPA shown in Figure 1H with the same region of the contralateral striatum in Fig. 1I and neuronal loss around the microdialysis probe. The neuronal loss was more marked for kainate and NMDA than for AMPA and was always confined within a space of 400-Km-diameter around the microdialysis probe (Fig. 1EYG ). This local effect was accompanied by remote microgliosis (compare Fig. 1J vs K) and neuronal loss (compare Fig. 1L vs M) in the ventralposterior complex of the thalamus. The action of glutamatergic agonists on microglia (Fig. 1N) and neurons (Fig. 1O ) of the thalamus was more marked for kainate and AMPA than for NMDA.
Striatal Effect of AMPA Administration
Administration of AMPA induced astrogliosis in the striatum that was observed in radial-like astrocytes that surrounded the perfused area ( Fig. 2A ) and in fibrous (Fig. 2D, F ) and protoplasmic astrocytes (compare regions near the perfused striatum [ Fig. 2G ] with more peripheral regions of the perfused striatum [ Fig. 2H ] or in the same region of the contralateral striatum [ Fig. 2I] ). Astrogliosis showed a 250% increase of GFAP immunoreactivity versus values for the same areas of the contralateral striatum (Fig. 2M) . Reactive astrogliosis was accompanied by reactive microgliosis in the striatum near the perfused areas (Fig. 2C, G) but not in striatal regions far away from the perfused region (Fig. 2H ) or in the same region of the contralateral striatum (Fig. 2I ). The astrogliosis that followed the AMPA perfusion was accompanied by a marked increase of GLU immunoreactivity in radial-like (Fig. 2B), fibrous (Fig. 2DYF) , and protoplasmic as trocytes. The high GLU immunoreactivity of protoplasmic astrocytes was not only observed in those located near the perfused area where no neuronal glutamatergic innervation was found (Fig. 1J ) but also in astrocytes located in more peripheral regions of the striatum, where it was (Fig. 2K) accompanied by normal immunoreactivity of glutamatergic terminals around striatal neurons; the terminals did not degenerate after AMPA administration in the more distant regions (Fig. 2K) . Glutamate immunoreactivity in the contralateral striatum was lower in astrocytes (Fig. 2L ) than in glutamatergic terminals around striatal neurons (Fig. 2L) . Glutamate immunoreactivity in astrocytes increased to values 60% higher than those computed in astrocytes of the same areas in the contralateral striatum (Fig. 2N) .
Striatal Effect of Kainate Administration
Kainate administration induced microgliosis (Fig. 3A) and astrogliosis in the striatum. Astrogliosis was observed in the radial-like astrocytes that surrounded the perfused area (Fig. 3B ) and in fibrous (Fig. 3D, E) and protoplasmic astrocytes (compare those shown by white arrows in regions near the perfused striatum [ Fig. 3G ] with those in more peripheral regions of the perfused striatum [ Fig. 3H ] or in the same region of the contralateral striatum astrocytes [ Fig. 3I] ). Astrogliosis induced a 120% increase of GFAP immunoreactivity (Fig. 3M ) and a 50% increase of GLU immunoreactivity (Fig 3N) versus values in astrocytes in the same areas of the contralateral striatum. The increase of GLU immunoreactivity was observed in radial-like (Fig. 3C) , fibrous (Fig. 3F) , and protoplasmic (Fig. 3J) astrocytes. The high GLU immunoreactivity was not only observed in protoplasmic astrocytes near the perfused area, where no neuronal glutamatergic innervation was found (Fig. 3J ), but also in more peripheral regions of the striatum where the high GLU immunoreactivity shown by astrocytes (Fig. 3H, K ) was accompanied by a normal immunoreactivity of glutamatergic terminals around striatal neurons. In these distant regions, the terminals did not degenerate after kainate administration (Fig. 3H, K) . Glutamate immunoreactivity in the contralateral striatum was lower in astrocytes (Fig. 3I, L) than in glutamatergic terminals around striatal neurons (Fig. 3I, L) .
Striatal Effect of NMDA Administration
Perfusion of NMDA in the striatum induced local microgliosis (Fig. 4A, G, J) and local astrogliosis. Astrogliosis was observed in radial-like astrocytes that surrounded the perfused area (Fig. 4B ) and in fibrous astrocytes (Fig. 4D, E ) and protoplasmic astrocytes (compare those indicated by white arrows in regions near the perfused striatum [ Fig. 4G ] with those in more peripheral regions of the perfused striatum [ Fig. 4H ] or in the same region of the contralateral striatum [ Fig. 4I] ). Astrogliosis induced a 50% increase of GFAP immunoreactivity (Fig. 4M) and a 20% increase of GLU immunoreactivity (Fig. 4N ) versus values in the same areas of the contralateral striatum. The increase of GLU immunoreactivity was observed in radial-like (Fig. 4C) , fibrous (Fig. 4F) , and protoplasmic (Fig. 4J) astrocytes. High GLU immunoreactivity was not only observed in protoplasmic astrocytes near the perfused area, where no neuronal glutamatergic innervation was found (Fig. 4J) , but also in more peripheral regions of the striatum, where it was (Fig. 4H, K) accompanied by GLU immunoreactivity of glutamatergic terminals (Fig. 4H, K) . Glutamate immunoreactivity in the contralateral striatum was lower in astrocytes (Fig. 4I, L) than in glutamatergic terminals around striatal neurons (Fig. 4I, L) .
Effect of Striatal Administration of NMDA, Kainate, and AMPA in the Thalamus
The perfusion of NMDA, kainate, and AMPA in the striatum induced microgliosis (Fig. 5A, C, I ) and astrocytosis (Fig. 5A, C, I ) in the ventral-posterior complex of the thalamus. Protoplasmic astrocytes of the thalamus of the brain side whose striatum was perfused with GLU agonists showed marked astrogliosis after administration of NMDA (compare the ipsilateral and contralateral thalamus in Fig. 5A, B) , kainate (Fig. 5C vs D) , and AMPA (Fig. 5I vs J) . The increase of GFAP immunoreactivity was approximately 120% to 150% in all groups (Fig. 5N) .
Reactive astrocytes in the thalamus also showed increased immunoreactivity for GLU (remote SIGA) after administration of NMDA (Fig. 5E), kainate (Fig. 5G ), or AMPA (Fig. 5K) . The GLU immunoreactivity of astrocytes in the thalamus contralateral to the perfused striatum was low and was generally lower than that observed in thalamic neurons (compare GLU immunoreactivity of astrocytes and neurons ( Fig. 5E vs F ; 5G vs H; and 5K vs L). There was a 25% to 45% increase of GLU immunoreactivity in all groups (Fig. 5N ).
DISCUSSION
We have demonstrated that GLU receptor agonists administered in the striatum induced degeneration of neurons and myelinated axons around the injection site that is accompanied by remote degeneration in thalamic regions (ventralposterior complex), the neurons of which project to the cortex across the striatum. Neuron loss in both the striatum and thalamus was associated with microgliosis and astrocytosis. Reactive astrocytes showed persistent GLU accumulation in the striatum (SIGA) and thalamus (remote SIGA) that persisted for up to 6 weeks after drug administration. This indicates that SIGA can be induced by neuronal degeneration even when it is retrogradely triggered from remote brain regions. Taken together, these data support the hypothesis that SIGA is induced by the excessive release of endogenous GLU.
The Extrasynaptic GLU Pool Induces Neuronal Degeneration, Microgliosis, and Astrocytosis in the Striatum and Thalamus
The perfusion of AMPA, kainate, or NMDA induced neuronal degeneration, microgliosis, and astrocytosis around the microdialysis probe. A similar effect was observed after striatal perfusion of GLU (29) . The present data suggest that these effects were probably induced by glutamatergic overstimulation of ionotropic receptors. The striatal parenchyma next to the microdialysis probe showed loss of protoplasmic astrocytes and the appearance of GFAP-positive processes not normally found in the striatum. These processes extended from the perfused striatal region to the surrounding tissue containing radial-type astrocytes (29) . As in our previous study, fibrous and protoplasmic astrocytes around the degenerated striatal areas increased in volume and in GFAP immunoreactivity, which also suggests involvement of ionotropic GLU receptors in the reactive astrogliosis induced by GLU (16, 29) .
Degeneration of striatal neurons induced by the glutamatergic agonists was accompanied by degeneration of neurons and microgliosis and astrocytosis in the ventral-posterior complex of the thalamus. The low GLU dose applied in the striatum produced only a small lesion of a few hundred Km around the microdialysis probe, indicating that drug diffusion was probably not the cause of the thalamic degeneration, which is millimeters away from the perfusion sites. Loss of myelinated tracts observed around the microdialysis probe (Black-Gold method, data not shown) suggests retrograde axonal degeneration as the likely mechanism for this thalamic cell loss. The striatal regions perfused with glutamatergic agonists are crossed by myelinated thalamo-cortical tracts that were probably damaged by the agonists. Indeed, overstimulation of ionotropic GLU receptors of oligodendrocytes can activate their degeneration (38, 39) and, consequently, the degeneration of neurons linked to them (38, 40Y42) . This might be the mechanism involved in the degeneration of neurons in the ventral-posterior complex of the thalamus, the axons of which probably crossed the perfused striatum, where they were likely exposed to toxic effects of the agonists. The finding that the thalamic degeneration was more marked after AMPA and kainate administration than after NMDA administration suggests that these receptors (previously found in oligodendrocytes [38, 40Y42] ) could be particularly relevant to the retrograde degeneration of myelinated thalamo-cortical axons. The microgliosis suggests that the thalamic neurons were phagocytosed, whereas the role of the astrocytosis in this degeneration is less evident and might be associated with the GLU accumulation observed in these cells.
Neuronal Degeneration Is Accompanied by a Persistent Accumulation of GLU in Striatal and Thalamic Astrocytes
Striatal SIGA has been observed in striatal astrocytes after administering GLU in the striatum (29) , an effect that could be induced by the astrocytic uptake of perfused GLU. Glutamate administration also degenerated glutamatergic input to the striatum, and the GLU accumulated in SIGA could be released by degenerated neurons rather than those that were exposed by perfusion. Here, SIGA was observed after administering GLU receptor agonists, suggesting that accumulated GLU may have been of endogenous origin. Selfinduced GLU accumulation induced by GLU perfusion was previously observed with a GLU concentration 10 times lower than that found in the synaptic cleft but 100 times higher than that found in the extrasynaptic space (1Y2 Kmol/L). The finding that endogenous GLU is able to induce SIGA increases the functional significance of this phenomenon.
Stimulation of astrocytic ionotrophic GLU receptors by the direct action of glutamatergic agonists could be involved in SIGA, but this mechanism cannot account for the thalamic SIGA that was generated without the local perfusion of drugs (remote SIGA). If astrocytic GLU receptors are involved in this remote SIGA, they must be activated by the previous release of GLU in the thalamus. Because glial GLU transporters are essential for maintaining a low concentration of GLU in the extracellular medium (43), they are probably involved in thalamic SIGA. Excitatory amino acid transporter 2 (EAAT2) is very abundant in astrocytes (44) and is the main agent for removing GLU from the extracellular medium (45) . Thus, this transporter is probably necessary for the accumulation of GLU in the early phase of astrocytic SIGA. However, the persistence of this accumulation for weeks is difficult to explain if the mechanisms involved in astrocytic catabolism of GLU remained operative. Downregulation of glutamine synthetase activity has been reported during reactive gliosis (46), a finding that has been observed in reactive astrocytes of the striatum after the local administration of GLU (29) . Thus, persistent inhibition of glutamine synthetase activity induced by a transient increase of extrasynaptic GLU is probably necessary for SIGA generation. It is likely that the mechanisms of GLU accumulation are the same in both striatal SIGA and remote thalamic SIGA: an excessive release Functional Relevance of SIGA Self-induced GLU accumulation could be considered the consequence of the neuroprotective activity of astrocytes that, by taking up GLU from the extracellular medium, prevents its excitotoxic action on GLU receptors of the surrounding cells. A GLU uptake increase could explain the transient increase of astrocytic GLU previously observed after GLU administration but not the persistent accumulation of GLU that characterizes SIGA. This accumulation is probably the consequence of selective inhibition of glutamine synthetase activity (29) , an inhibition that is selective and does not affect GLU catabolism to alanine (29) . High glutamine concentrations can inhibit the metabolic activity of mitochondria (47) , thereby damaging neurons and disturbing brain activity (e.g. inducing hepatic encephalopathy) (48Y50), which suggests that glutamine synthetase inhibition and SIGA may be adaptive phenomena that prevent glutamine toxicity. Thus, both the uptake of extracellular GLU (which prevents the excitotoxic action of extracellular GLU) and the inhibition of the intracellular metabolism of GLU (which prevents the toxic effects of its metabolite glutamine) can be considered to be neuroprotective mechanisms. However, the result of these activities is massive and persistent accumulation of GLU in astrocytes. In view of the fact that a number of stimuli (swelling, ischemia, reactive oxygen species, microglia activation) and mechanisms (vesicular release, reverse operation of GLU transporters, opening of anion channels or hemichannels) result in astrocytic release of GLU, the astrocyte effects may be considered as a potential danger to the tissue. Indeed, previous in vitro studies on hippocampal cells suggested that GLU release from SIGA astrocytes could induce massive extracellular increase of GLU, followed by excitotoxicity (51) , and our present data suggest that this could also occur in the striatum and the thalamus. Thus, SIGA may have some adaptive consequences but may also have pathogenetic effects. The ample GLU reservoir normally stored in astrocytes can be released to the extracellular extrasynaptic space where, after diffusing long distances, can induce longlasting effects on remote GLU receptors (52Y58). The astrocyte pool of GLU could have major excitotoxic actions (14, 21, 59 ) that would be dramatically amplified by SIGA. In such a scenario, any circumstance that increases extracellular GLU in a persistent way (e.g. in Parkinson disease and Huntington disease) or in a transient but severe manner (e.g. in epilepsy) could induce SIGA. This phenomenon should be considered in the therapeutic strategies to prevent the progression of these conditions.
